-continued

Nasal MDI with Azelastine and steroid		
Sr. No.	Ingredients	Quantity in mcg
	HFA 134a	q.s.
	Alcohol	(up to 5%)

Insufflatable powders containing Azelastine and Steroid:

EXAMPLE 12

Sr. No.	Ingredients	Quantity (% w/w)
	Azelastine Hydrochloride (Micronized)	140 mcg
	Fluticasone propionate	50 mcg
	Lactose	q.s. (up to 25 mcg)

EXAMPLE 13

Sr. No.	Ingredients	Quantity (% w/w)
	Azelastine Hydrochloride (Micronized)	140 mcg
	Fluticasone propionate	100 mcg
	Mannitol	q.s. (up to 30 mcg)

EXAMPLE 14

Sr. No.	Ingredients	Quantity (% w/w)
	Azelastine Hydrochloride (Micronized)	140 mcg
	Fluticasone propionate	250 mcg
	Lactose	q.s. (up to 30 mcg)

What is claimed is:

1. A method for the prophylaxis or treatment in a mammal of a condition for which administration of one or more antihistamines and/or one or more steroids is indicated, comprising intranasal administration to said mammal of a therapeutically effective amount of a pharmaceutical composition comprising (a) azelastine, or a pharmaceutically acceptable salt thereof; and (b) pharmaceutically acceptable ester of fluticasone.

2. The method of claim **1**, wherein said pharmaceutically acceptable salt of azelastine is azelastine HCl.

3. The method of claim **1**, wherein said pharmaceutically acceptable ester of fluticasone is fluticasone propionate or fluticasone valerate.

4. The method of claim **1**, wherein said pharmaceutical composition is in the form of a nasal spray.

5. The method of claim **1**, wherein said pharmaceutical composition is in the form of nasal drops.

6. The method of claim **1**, wherein said pharmaceutical composition is the form of an insufflation powder.

7. The method of claim **1**, wherein said mammal is a human.

8. The method of claim **1**, wherein said condition is allergic rhinitis.

9. The method of claim **1**, wherein said condition is allergic conjunctivitis.

10. The method of **1**, wherein said pharmaceutical composition comprises a pharmaceutically acceptable ester of fluticasone in an amount from about 50 micrograms/ml to about 5 mg/ml of the composition.

11. The method of claim **10**, wherein the pharmaceutical composition has a particle size of less than 10 μm.

12. The method of claim **1**, wherein said pharmaceutical composition is an aqueous suspension comprising from about 0.0005% to about 2% (weight/weight) of azelastine or a pharmaceutically acceptable salt of azelastine, and from about 0.0357% to about 1.5% (weight/weight) of pharmaceutically acceptable ester of fluticasone.

13. The method of claim **12**, wherein said pharmaceutical composition is an aqueous suspension comprising from about 0.001% to about 1% (weight/weight) of azelastine or a pharmaceutically acceptable salt of azelastine, and from about 0.0357% to about 1.5% (weight/weight) of a pharmaceutically acceptable ester of fluticasone.

14. The method of claim **12**, wherein said pharmaceutical composition is an aqueous suspension comprising 0.1% or 0.15% (weight/weight) of azelastine HCl and from about 0.0357% to about 1.5% (weight to weight) of fluticasone propionate or fluticasone valerate.

15. The method of claim **5**, wherein said pharmaceutical composition further comprises at least one surfactant selected from the group consisting of a polysorbate surfactant, poloxamer surfactant, and combinations thereof.

16. The method of claim **15**, wherein said pharmaceutical composition comprises from about 50 micrograms to about 1 milligram of said surfactant per ml of the formulation.

17. The method of claim **1**, wherein said pharmaceutical composition further comprises at least one isotonic agent selected from the group consisting of sodium chloride, saccharose, glucose, glycerine, sorbitol, 1,2-propylene glycol, and combinations thereof.

18. The method of claim **1**, wherein said pharmaceutical composition further comprises at least one additional component selected from the group consisting of a buffer, a preservative, a suspending agent, a thickening agent, and combinations thereof.

19. The method of claim **18**, wherein said buffer is a citric acid-citrate buffer.

20. The method of claim **18**, wherein said preservative is selected from the group consisting of edetic acid and its alkali salts, lower alkyl p-hydroxybenzoates, chlorhexidine, phenyl mercury borate, benzoic acid or a salt thereof, a quaternary ammonium compound, sorbic acid or a salt thereof, and combinations thereof.

21. The method of claim **18**, wherein said suspending agent or thickening agent is selected from the group consisting of cellulose derivatives, gelatin, polyvinylpyrrolidone, tragacanth, ethoxose, alginic acid, polyvinyl alcohol, polyacrylic acid, pectin, and combinations thereof.

22. The method of claim **1**, wherein said formulation comprises a pH of from 3 to 7.

23. The method of claim **1**, wherein said formulation comprises a pH from 4.5 to 6.5.

24. The method of claim **15**, wherein said surfactant comprises a polysorbate.